Targarona E M, Pons M D, Gonzalez G, Boix L, Marco V, Marco C
Department of Surgery, Hospital de Mutua de Terrassa, University of Barcelona, Spain.
Hepatogastroenterology. 1991 Apr;38(2):165-9.
The 5-year survival rate of patients with exocrine pancreatic cancer after surgery is less than 5%, in patients treated with radical surgery, with or without adjuvant therapy. It has been well documented clinically and experimentally that sex hormones influence the physiology of the exocrine pancreas. Hormone manipulation inhibits the growth of human pancreatic cancer in nude mice. Several nonrandomized studies have suggested the efficacy of antihormone therapy in the treatment of advanced pancreatic cancer. However, the existence of sex hormone receptors in exocrine pancreatic cancer has been a matter of controversy. This study was designed to investigate the presence of sex hormone receptors (estrogens, progesterone and androgens in normal pancreas and exocrine pancreatic cancer, using two different methods: immunohistochemistry and enzyme immunoassay. Twenty-eight biopsies of normal pancreas and 15 biopsies of exocrine pancreatic cancer were studied. Estrogen receptors and progesterone receptors were measured by enzyme immunoassay, using specific monoclonal antibodies. Androgen receptors were determined by radioligand assay. Sixteen biopsies of normal pancreas and 12 biopsies of exocrine pancreatic cancer were studied by immunohistochemistry. In exocrine pancreatic cancer we could not detect estrogen receptors or progesterone receptors, either by enzyme immunoassay or immunohistochemistry. Androgen receptors were always negative (less than 2 fm/mg). In the normal pancreas, 5 out of 28 cases showed increased levels of progesterone receptors (greater than 10 fm/mg) as measured by enzyme immunoassay. Immunohistochemistry revealed progesterone receptors in the pancreatic islets of 16 normal pancreases studied. Nuclear staining was observed in more than 70% of the cells. Estrogen receptors were always negative by immunohistochemistry and enzyme immunoassay in the normal pancreas.2+n
外分泌性胰腺癌患者术后的5年生存率低于5%，无论是否接受辅助治疗，接受根治性手术的患者亦是如此。临床和实验均已充分证明，性激素会影响外分泌胰腺的生理功能。激素调控可抑制裸鼠体内人胰腺癌的生长。多项非随机研究表明，抗激素疗法在晚期胰腺癌治疗中具有疗效。然而，外分泌性胰腺癌中是否存在性激素受体一直存在争议。本研究旨在采用免疫组织化学和酶免疫测定这两种不同方法，调查正常胰腺和外分泌性胰腺癌中性激素受体（雌激素、孕激素和雄激素）的存在情况。研究了28份正常胰腺活检标本和15份外分泌性胰腺癌活检标本。使用特异性单克隆抗体通过酶免疫测定法测量雌激素受体和孕激素受体。通过放射性配体测定法测定雄激素受体。采用免疫组织化学方法研究了16份正常胰腺活检标本和12份外分泌性胰腺癌活检标本。在外分泌性胰腺癌中，无论是通过酶免疫测定法还是免疫组织化学方法，均未检测到雌激素受体或孕激素受体。雄激素受体始终呈阴性（低于2 fm/mg）。在正常胰腺中，通过酶免疫测定法测量，28例中有5例显示孕激素受体水平升高（大于10 fm/mg）。免疫组织化学显示，在所研究的16份正常胰腺的胰岛中存在孕激素受体。在超过70%的细胞中观察到核染色。在正常胰腺中，通过免疫组织化学和酶免疫测定法检测，雌激素受体始终呈阴性。
Zotero 插件